Horizon Therapeutics (NASDAQ:HZNP) reported Q1 EPS of $1.34, $0.20 better than the analyst estimate of $1.14. Revenue for the quarter came in at $885.2 million versus the consensus estimate of $874.41 million.
GUIDANCE:
Horizon Therapeutics maintains its FY2022 revenue outlook of $3.9-4 billion, versus the consensus of $3.98 billion.